|
rs3892097
|
CYP2D6
*4
|
Major enzyme for metabolizing ~25% of medications including opioids, antidepr...
|
Pharmacogenomics
|
|
Established
|
|
rs1065852
|
CYP2D6
*10
|
Decreased function CYP2D6 variant common in Asian populations
|
Pharmacogenomics
|
|
Established
|
|
rs4244285
|
CYP2C19
*2
|
No-function CYP2C19 variant affecting PPIs, clopidogrel, and some antidepress...
|
Pharmacogenomics
|
|
Established
|
|
rs1042713
|
ADRB2
Arg16Gly
|
Beta-2 adrenergic receptor variant affecting receptor downregulation, exercis...
|
Fitness & Body
|
|
Strong
|
|
rs12248560
|
CYP2C19
*17
|
Increased function CYP2C19 variant - rapid/ultrarapid metabolizer
|
Pharmacogenomics
|
|
Established
|
|
rs700518
|
CYP19A1
Val80
|
Synonymous variant in aromatase gene affecting estrogen production, bone dens...
|
Hormones & Sleep
|
|
Strong
|
|
rs1799853
|
CYP2C9
*2
|
Decreased function variant affecting warfarin, phenytoin, and NSAIDs
|
Pharmacogenomics
|
|
Established
|
|
rs1800629
|
TNF
-308 G>A
|
Promoter variant increasing TNF-alpha production 2-3 fold, associated with au...
|
Immune & Gut
|
|
Strong
|
|
rs523349
|
SRD5A2
V89L
|
Missense variant reducing 5-alpha-reductase type 2 enzyme activity, affecting...
|
Hormones & Sleep
|
|
Moderate
|
|
rs1057910
|
CYP2C9
*3
|
No-function CYP2C9 variant with major warfarin implications
|
Pharmacogenomics
|
|
Established
|
|
rs5186
|
AGTR1
A1166C
|
3' UTR variant in angiotensin II type 1 receptor affecting blood pressure reg...
|
Heart & Inflammation
|
|
Moderate
|
|
rs762551
|
CYP1A2
*1F
|
Caffeine metabolism - affects how quickly you process caffeine
|
Pharmacogenomics
|
|
Strong
|
|
rs4149056
|
SLCO1B1
*5
|
Statin transport - affects muscle side effect risk with statins
|
Pharmacogenomics
|
|
Established
|
|
rs6311
|
HTR2A
-1438G>A
|
Regulatory variant in serotonin 2A receptor gene affecting SSRI side effects ...
|
Brain & Mental Health
|
|
Moderate
|
|
rs9923231
|
VKORC1
-1639G>A
|
Warfarin sensitivity - determines initial dosing
|
Pharmacogenomics
|
|
Established
|
|
rs671
|
ALDH2
*2
|
Alcohol metabolism - flush reaction and cancer risk
|
Pharmacogenomics
|
|
Established
|
|
rs16947
|
CYP2D6
*2
|
Common CYP2D6 variant defining the *2 allele; previously considered normal-fu...
|
Pharmacogenomics
|
|
Strong
|
|
rs5030655
|
CYP2D6
*6
|
Frameshift deletion causing no enzyme function, defining poor metabolizer sta...
|
Pharmacogenomics
|
|
Established
|
|
rs2066853
|
AHR
Arg554Lys
|
Aryl hydrocarbon receptor variant in the transactivation domain that alters A...
|
Hormones & Sleep
|
|
Moderate
|
|
rs28371725
|
CYP2D6
*41
|
Intronic splice variant causing decreased CYP2D6 enzyme activity through aber...
|
Pharmacogenomics
|
|
Established
|
|
rs776746
|
CYP3A5
*3
|
Splice site variant creating a non-functional CYP3A5 enzyme, dramatically aff...
|
Pharmacogenomics
|
|
Established
|
|
rs3745274
|
CYP2B6
516G>T
|
Decreased-function variant affecting metabolism of efavirenz, methadone, bupr...
|
Pharmacogenomics
|
|
Established
|
|
rs3918290
|
DPYD
*2A
|
Most critical pharmacogenomic variant causing complete loss of DPD enzyme fun...
|
Pharmacogenomics
|
|
Established
|
|
rs67376798
|
DPYD
D949V
|
Decreased-function variant reducing DPD enzyme activity ~30%, requiring 50% f...
|
Pharmacogenomics
|
|
Established
|
|
rs1142345
|
TPMT
*3C
|
No-function variant causing deficient thiopurine methylation; most common TPM...
|
Pharmacogenomics
|
|
Established
|
|
rs2231142
|
ABCG2
Q141K
|
Reduces ABCG2 transporter function affecting rosuvastatin levels and uric aci...
|
Pharmacogenomics
|
|
Established
|
|
rs2108622
|
CYP4F2
V433M (*3)
|
Reduces vitamin K metabolism, requiring higher warfarin doses to achieve anti...
|
Pharmacogenomics
|
|
Established
|
|
rs1799971
|
OPRM1
A118G
|
Mu-opioid receptor variant affecting opioid response, pain sensitivity, and p...
|
Pharmacogenomics
|
|
Moderate
|
|
rs1045642
|
ABCB1
C3435T
|
Synonymous variant in P-glycoprotein affecting drug efflux pump expression an...
|
Pharmacogenomics
|
|
Moderate
|
|
rs1801280
|
NAT2
I114T
|
Phase II detoxification - acetylation of aromatic amines and certain medications
|
Methylation & Detox
|
|
Established
|
|
rs1799930
|
NAT2
R197Q
|
Slow acetylator variant affecting Phase II detoxification capacity
|
Methylation & Detox
|
|
Established
|
|
rs4148323
|
UGT1A1
*6 Gly71Arg
|
Phase II glucuronidation enzyme that metabolizes bilirubin and many drugs inc...
|
Pharmacogenomics
|
|
Established
|
|
rs1208
|
NAT2
R268K
|
NAT2 acetylation speed tag SNP - marks rapid vs slow acetylator haplotypes
|
Methylation & Detox
|
|
Established
|
|
rs2740574
|
CYP3A4
*1B -392A>G
|
Promoter variant affecting CYP3A4 expression, most common in African populations
|
Pharmacogenomics
|
|
Moderate
|
|
rs116855232
|
NUDT15
Arg139Cys
|
Nucleotide diphosphatase that inactivates toxic thiopurine metabolites; reduc...
|
Pharmacogenomics
|
|
Established
|
|
rs5219
|
KCNJ11
E23K
|
Controls the pancreatic beta-cell potassium channel that regulates insulin se...
|
Nutrition & Metabolism
|
|
Strong
|